Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants-Reference-Cited by-同舟云学术

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants

Published:2021-10-26 Issue:1 Volume:89 Page:71-81
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Hibma Jennifer E.^ORCID,O’Gorman Melissa,Nepal Sunil,Pawlak Sylvester,Ginman Katherine,Pithavala Yazdi K.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-021-04368-1.pdf

Reference13 articles.

1. Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M et al (2015) PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 28:70–81. https://doi.org/10.1016/j.ccell.2015.05.010

2. Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA et al (2019) Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol 20:1691–1701. https://doi.org/10.1016/s1470-2045(19)30655-2

3. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR et al (2018) Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol 19:1654–1667. https://doi.org/10.1016/s1470-2045(18)30649-1

4. Syed YY (2019) Lorlatinib: first global approval. Drugs 79:93–98. https://doi.org/10.1007/s40265-018-1041-0

5. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ, CROWN Trial Investigators (2020) First-line Lorlatinib or Crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383(21):2018–2029. https://doi.org/10.1056/nejmoa2027187

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring intermolecular interaction between transporter protein, bovine serum albumin and antitumor drug Lorlatinib: Multispectral approaches combined with molecular simulation;Journal of Molecular Structure;2025-02

2. Brain-Penetrant Macrocycles: Design Considerations, Future Prospects, and Call for Papers;Journal of Medicinal Chemistry;2024-05-07

3. Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib;Frontiers in Pharmacology;2023-11-22

4. Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase‑positive non‑small cell lung cancer: A case report;Oncology Letters;2023-10-23

5. Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug–Drug Interaction and Improving Clinical Practice;Clinical Pharmacokinetics;2023-01